Redox-reactive antiphospholipid antibody differences between serum from Alzheimer's patients and age-matched controls

References

• McIntyre JA, Wagenknecht DR, Faulk WP. Autoantibodies unmasked by redox reactions. J Autoimmun. 2005; 24:311–317.
   PubMed Web of Science ®Google Scholar
• Cabiedes J, Cabral AR, Alarcon-Segovia D. Hidden anti-phospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments. Eur J Immunol. 1998; 7:2108–2114.
   Google Scholar
• Lorber M, Shoenfeld Y. Hidden autoantibodies. Clin Rev Allergy Immunol. 2000; 1:51–58.
   Google Scholar
• Tomer Y, Shoenfeld Y. The significance of natural autoantibodies. Immunol Invest. 1988; 5:389–424.
   Google Scholar
• McIntyre JA, Chapman J, Shavit E, Hamilton RL, DeKosky ST. Redox-reactive autoantibodies in Alzheimer's patient's cerebrospinal fluids: Preliminary studies. Autoimmunity. 2007; 40:390–396.
   PubMed Web of Science ®Google Scholar
• Sultana R, Perluigi M, Butterfield DA. Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Aβ (1-42). J Chromatog B. 2006; 833:3–11.
   PubMed Web of Science ®Google Scholar
• Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol. 2008; 21:172–188.
   PubMed Web of Science ®Google Scholar
• Oomen HA, Wekking EM, de Jong J, Smeenk RJ. Screening psychiatric admissions for anticardiolipin antibody. Psych Res. 1995; 58 1: 83–88 Sep 8.
   PubMed Web of Science ®Google Scholar
• Juby A, Davis P, Genge T, McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus6:482–485.
   Google Scholar
• Juby AG, Davis P. Prevalence and disease associations of certain autoantibodies in elderly patients. Clin Invest Med. 1998; 21:4–11.
   PubMed Web of Science ®Google Scholar
• Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord. 2000; 11:36–38.
   PubMed Web of Science ®Google Scholar
• McIntyre JA, Wagenknecht DR, Waxman DW. Frequency and specificities of antiphospholipid antibodies (aPL) in volunteer blood donors. Immunobiology. 2003; 207:59–63.
   PubMed Web of Science ®Google Scholar
• Steinberg D, Colla P. CART: Tree-structured non- parametric data analysis. San Diego, CA: Salford Systems; 1995.
   Google Scholar
• Breiman L, Friedman J, Olshen R, Stone C. Classification and regression trees. Pacific Grove, CA: Wadsworth Publishing Co. 1984.
   Google Scholar
• Fisher RA. The use of multiple measurements in taxonomic problems. Ann Eugen. 1936; 7:179–188.
   Google Scholar
• McIntyre JA, Faulk WP. Redox-reactive autoantibodies: Biochemistry, characterization, and specificities. Clin Rev Allerg Immunol 2008, online..
   Google Scholar
• Pena-Casanova J. Alzheimer's disease assessment scale-cognitive in clinical practice. Int Psychogeriatr. 1997; 9:105–114.
   PubMedGoogle Scholar
• Tombaugh TN, McIntyre NJ. The mini-mental state examination: A comprehensive review. J Am Geriatr Soc. 1992; 40:922–935.
   PubMed Web of Science ®Google Scholar
• Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Meltzer CC, Wisniewski S, Kamboh MI, DeKosky ST. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology. 2000; 55:1854–1862.
   Google Scholar
• Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Meltzer CC, Wisniewski S, Kamboh MI, DeKosky ST. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: II. Neurology. 2000; 55:1863–1869.
   Google Scholar
• , Consensus report of the working group on molecular and biochemical markers of Alzheimer's disease. The Ronald and Nancy Reagan Research Institute of Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998; 19:109–116.
   PubMedGoogle Scholar
• Formichi P, Battisti C, Radi E, Federico A. Cerebrospinal fluid tau Aβ, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol. 2006; 208:39–46.
   PubMed Web of Science ®Google Scholar
• Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007; 64:354–362.
   PubMedGoogle Scholar
• Kawarabayashi T, Shoji M. Plasma biomarkers of Alzheimer's disease. Curr Opin Psych. 2008; 21:260–267.
   PubMed Web of Science ®Google Scholar
• Bailey P. Biological markers in Alzheimer's disease. Can J Neurol Sci. 2007; 34:S72–S76.
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6:734–746.
   PubMed Web of Science ®Google Scholar
• Jellinger KA, Janetzky B, Attems J, Kienzl E. Biomarkers for early diagnosis of Alzheimer's disease: ‘ALZheimer ASssociated gene’ — a new blood biomarker. J Cell Mol Med. 2008; 12:1094–1117.
   PubMed Web of Science ®Google Scholar
• Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Med. 2007; 11:1359–1362.
   Google Scholar
• Blennow M, de Leon H, Zetterberg H. Alzheimer's disease. Lancet. 2006; 368:387–403.
   PubMed Web of Science ®Google Scholar
• McIntyre JA. The appearance and disappearance of antiphospholipid antibodies subsequent to oxidation-reduction reactions. Thromb Res. 2004; 114:579–587.
   PubMed Web of Science ®Google Scholar
• McIntyre JA, Wagenknecht DR, Faulk WP. Redox-reactive autoantibodies: Detection and physiological relevance. Autoimmun Rev. 2006; 5:76–83.
   PubMed Web of Science ®Google Scholar
• Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL. Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. J Lipid Res. 2007; 48:2485–2498.
   PubMed Web of Science ®Google Scholar
• Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res. 1995; 698:223–226.
   PubMed Web of Science ®Google Scholar
• Qamar T, Gharavi AE, Levy RA, Lockshin MD. Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds. J Clin Immunol. 1990; 10:200–203.
   PubMed Web of Science ®Google Scholar
• Kerr E, Craig D, McGuinness B, Dynan KB, Fogarty D, Johnston JA, Passmore AP. Reduced estimated glomerular filtration rate in Alzheimer's disease. Int J Geriatr Psych. 2009 (in press).
   PubMed Web of Science ®Google Scholar